[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338029-105":59,"doc-detail-338029-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognostic-relevance-and-validation-of-arpc1a-in-the-progression-of-low-grade-glioma","Prognostic relevance and validation of ARPC1A in the progression of low-grade glioma","","Low-grade glioma (LGG) is a grade II–III glioma with distinct clinical and molecular features, yet its prognostic biology remains incompletely defined. This study investigates mitochondrial-related genes, focusing on ARPC1A and associated candidates (SLBP, COMMD7, LSM4, TOMM34, RPP40, FKBP1A, TBCA), using bioinformatics analyses plus RT-PCR validation. Differential expression supported construction of a nomogram integrating age, WHO grade, IDH mutation, 1p/19q co-deletion, and ARPC1A expression to estimate 1-, 3-, and 5-year survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-relevance-and-validation-of-arpc1a-in-the-progression-of-low-grade-glioma/338029/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-relevance-and-validation-of-arpc1a-in-the-progression-of-low-grade-glioma/338029.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the study on ARPC1A in low-grade glioma?","Question",{"text":112,"@type":113},"To explore how mitochondrial-related genes, especially ARPC1A, contribute to the prognosis and progression of low-grade glioma using bioinformatics and experimental validation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is prognostic risk for low-grade glioma predicted in the paper?",{"text":117,"@type":113},"A nomogram is built and validated using risk factors including age, WHO grade, IDH mutation status, 1p/19q co-deletion status, and ARPC1A expression to predict 1-, 3-, and 5-year overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental approaches are used to test ARPC1A-related biological effects?",{"text":121,"@type":113},"Transfection, CCK-8 proliferation assays, flow cytometry for apoptosis, western blotting for MAPK signaling involvement, and gene expression validation via RT-PCR are used.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338029,1790912975,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 14  \nResearch Paper  \nPrognostic relevance and validation of ARPC1A in the progression of low-grade glioma  \nJingyuan Dai1, Jiahui Gao2, Hongchao Dong3  \n1School of Computer Science and Information Systems, Northwest Missouri State University, Missouri, MO 64468, USA  \n2Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Hebei, China 3Shaanxi Second People’s Hospital, Shaanxi, China  \nCorrespondence to: Hongchao Dong; email: [601039350@qq.com](601039350@qq.com), [https://orcid.org/0009-0006-4009-3100](https://orcid.org/0009-0006-4009-3100)[ ](https://orcid.org/0009-0006-4009-3100)[Keywords:](Keywords: low-grade glioma)[ low-grade glioma](Keywords: low-grade glioma), mitochondria-genes, ARPC1A, MAPKinases, nomogram, prognosis, TCGA, CGGA  \nReceived: January 8, 2024 Accepted: April 15, 2024 Published: June 19, 2024  \nCopyright: © 2024 Dai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nLow-grade glioma (LGG) is a grade II-III glioma accompanied by distinct clinical and molecular characteristics and the studies related to its prognosis are still unclear. The objective of this study is to explore the involvement of mitochondrial-related genes SLBP, COMMD7, LSM4, TOMM34, RPP40, FKBP1A, ARPC1A, and TBCA for the prognosis of LGG. We detected differences in the expression of some of the genes by analyzing the bioinformatics dataset and combining it with RT-PCR experiments. Subsequently, a nomogram was constructed and validated for the clinical relevance of risk factors such as age, WHO grade, IDH mutation status, Ch.1p19q co-deletion status, and high and low expression of ARPC1A to predict the 1-, 3-, 5-year overall survival and prognostic relevance of ARPC1A. Gene set enrichment analysis was performed for the relevant datasets pertinent to the expression of ARPC1A to elucidate the cancer-promoting pathways involved in the LGG through KEGG and GO analysis. Transfection assays, CCK-8 assays, and flow cytometry were used to determine the proliferation rate, and apoptosis rate of the HS683 and SW1783 cell lines respectively. Western blotting was used to examine the involvement of the cancer-promoting activity of ARPC1A through MAPK signaling. In this study, the prognostic value of ARPC1A in LGG was found by bioinformatics analysis combined with experimental approach analysis and may be a significant independent risk factor. ARPC1A fosters a higher LGG proliferation rate that may control the MAP kinase signaling and could be a prominent biomarker for LGG. Future studies are warranted to explore its clinical implications.  \nINTRODUCTION  \nGliomas are aggressive primary tumors confined to the central nervous system and their incidence rates have been increasing and account for 40% to 50% of the total incidence of intracranial tumors. These cancers are highly malignancy and cause a decline in the overall survival of patients worldwide due to the lack of suitable early prognostic strategies [1–4] . Mainly, the LGG is a grade II-III glioma composed of different clinical and molecular characteristics [5] . A growing number of WHO low-grade gliomas are incidentally  \nobserved but some of the patients do not manifest LGG-related symptoms and these incidental LGGs are uncommon and account for 3.8–10.4% of all the LGGs [6–13] . Clinical treatment modalities for gliomas include surgery, radiotherapy and chemotherapy and their implications have failed to provide effective clinical outcomes due to poor clinical prognosis [14, 15] . Surgical treatment is one of the primary therapeutic modalities for patients who do not manifest tumor-related symptoms [16–21] . Survival-related factors could help determine surgical decisions. A few retrospective reports d","cbCaioG1fpSqmPes","https://ap.wps.com/l/cbCaioG1fpSqmPes","pdf",2727157,23,"English","# Abstract\n# Introduction\n## Low-grade glioma clinical background\n## Role of mitochondria in cancer progression\n## Mitochondrial genes and glioma prognosis","[{\"question\":\"What is the main purpose of the study on ARPC1A in low-grade glioma?\",\"answer\":\"To explore how mitochondrial-related genes, especially ARPC1A, contribute to the prognosis and progression of low-grade glioma using bioinformatics and experimental validation.\"},{\"question\":\"How is prognostic risk for low-grade glioma predicted in the paper?\",\"answer\":\"A nomogram is built and validated using risk factors including age, WHO grade, IDH mutation status, 1p/19q co-deletion status, and ARPC1A expression to predict 1-, 3-, and 5-year overall survival.\"},{\"question\":\"What experimental approaches are used to test ARPC1A-related biological effects?\",\"answer\":\"Transfection, CCK-8 proliferation assays, flow cytometry for apoptosis, western blotting for MAPK signaling involvement, and gene expression validation via RT-PCR are used.\"}]","Prognostic relevance and validation of ARPC1A in the progression of low-grade glioma | PDF",1790021626,58]